{"organizations": [], "uuid": "4956178af88f2c0e9fa3665aca59e01545d875e0", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-edge-therapeutics-reports-quarterl/brief-edge-therapeutics-reports-quarterly-loss-per-share-0-67-idUSASC09YHZ", "country": "US", "domain_rank": 408, "title": "BRIEF-Edge Therapeutics Reports Quarterly Loss Per Share $0.67", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-01T13:37:00.000+03:00", "replies_count": 0, "uuid": "4956178af88f2c0e9fa3665aca59e01545d875e0"}, "author": "", "url": "https://www.reuters.com/article/brief-edge-therapeutics-reports-quarterl/brief-edge-therapeutics-reports-quarterly-loss-per-share-0-67-idUSASC09YHZ", "ord_in_thread": 0, "title": "BRIEF-Edge Therapeutics Reports Quarterly Loss Per Share $0.67", "locations": [], "entities": {"persons": [], "locations": [], "organizations": [{"name": "reuters staff", "sentiment": "none"}, {"name": "piper jaffray & co", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "edge therapeutics inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 1, 2018 / 10:38 AM / Updated 12 minutes ago BRIEF-Edge Therapeutics Reports Quarterly Loss Per Share $0.67 Reuters Staff\nMay 1 (Reuters) - Edge Therapeutics Inc:\n* EDGE THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS * QTRLY LOSS PER SHARE BASIC AND DILUTED $0.67\n* SAYS BOARD CONDUCTING A COMPREHENSIVE REVIEW OF STRATEGIC ALTERNATIVES FOCUSED ON MAXIMIZING STOCKHOLDER VALUE\n* SAYS INTENDS TO STREAMLINE ITS OPERATIONS IN ORDER TO PRESERVE ITS CASH RESOURCES\n* SAYS HAS RETAINED PIPER JAFFRAY & CO. TO ACT AS ITS FINANCIAL ADVISOR TO ASSIST WITH THIS REVIEW PROCESS Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-05-01T13:37:00.000+03:00", "crawled": "2018-05-01T13:58:46.018+03:00", "highlightTitle": ""}